Company Overview and News

0
Core Exploration receives a speculative buy from RM Research

2018-07-20 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has been rated a speculative buy with a price target of 6.5 cents per share by Perth-based RM Research.
CXO

0
Core Exploration sees strong financials and short payback period for Finniss Lithium Project

2018-07-16 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) managing director Stephen Biggins speaks with Proactive Investors about the key Finniss Lithium Project.
CXO

0
Core Exploration’s drilling confirms further extensions to the Grants Lithium Deposit

2018-07-06 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has discovered significant extensions to the Grants Lithium Deposit, part of its Finniss Lithium Project near Darwin in the Northern Territory.
CXO

51
Lithium Junior Miner News For The Month Of June 2018

2018-06-27 seekingalpha
Lithium market news: Joe Lowry significantly raised his new lithium demand forecast to ~800K MT LCE in 2025. Indian State-owned firms mandated to acquire overseas lithium and cobalt.
NI LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS MNIKF PLU HNR AMLM 9984 AVL ALB DMNXF MALRY EEYMF SFTBF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS NNO DJI PDDTF NTTHF NNOMF CYP MALRF ORE AVZ AJM

0
Core Exploration takes investors through dominant position in emerging lithium province

2018-06-27 proactiveinvestors.com.au
Core Exploration Ltd's (ASX:CXO) managing director, Stephen Biggins, presented to investors at Proactive's CEO Sessions this week in Melbourne and Sydney.
CXO

0
Core Exploration’s pre-feasibility study delivers robust economics for Grants Lithium Deposit

2018-06-25 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has delivered the pre-feasibility study (PFS) for the Grants Lithium Deposit, a key component of its Finniss Lithium Project, near Darwin in the Northern Territory.
CXO

0
Core Exploration Has Large Exploration Potential And A $2.4B Market Cap Chinese Off-Take Equity Partner

2018-06-22 seekingalpha
Core Exploration has a potentially large lithium project in Northern Territory with plenty of exploration upside.
CXO AXE IGO IIDDY ELXPF SAU RSG RMGGY EXR DRM RMGGF SUTHF IVR

0
Core Exploration begins drilling to expand Finniss lithium resource

2018-06-05 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has commenced a drilling program to expand the lithium resource at its Finniss Lithium Project in the Northern Territory.
CXO

0
Core Exploration expands lithium JORC resource by 70%

2018-05-23 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has received a maiden resource estimate for the BP33 lithium deposit of 1.4 million tonnes grading 1.4% lithium oxide.
CXO

0
Core Exploration director increases stake via share purchase plan

2018-05-14 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) director, Stephen Biggins, has purchased 188,680 shares for $10,000 by participating in the company’s share purchase plan.
CXO

2
Lithium next boom resource from the mining powerhouse of Western Australia

2018-05-09 proactiveinvestors.com.au
The key new generation battery ingredient of lithium is set to become Western Australia’s next boom metal, following in the steps of gold, nickel and iron ore.
LIT KDR LMMFF CXO NMT

0
Core Exploration doubles Grants resource as it prepares PFS with an eye to near-term production

2018-05-09 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has consistently delivered positive news in 2018 and just this week shareholders were encouraged by additional financial support from a key Chinese investor.
CXO

0
Core Exploration doubles indicated lithium resource at Grants

2018-05-08 proactiveinvestors.com.au
Core Exploration Ltd (ASX:CXO) has doubled the indicated lithium resource at the Grants lithium deposit within its Finniss Lithium Project in the Northern Territory.
CXO

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:CXO / CORE EXPLORATION LIMITED on message board site Silicon Investor.

CXO Colorado Resources